Effects of once-weekly subcutaneous semaglutide on coronary artery disease outcomes in patients with type 2 diabetes with or at high risk for cardiovascular disease: Insights from the SUSTAIN-6 trial

Diabetes Obes Metab. 2023 Apr;25(4):1117-1120. doi: 10.1111/dom.14941. Epub 2022 Dec 23.

Authors

Ahmed A Kolkailah^{1

2}, Ildiko Lingvay³, Idit Dobrecky-Mery⁴, Alona Aharonovich⁵, Jens-Peter David⁵, Cecilie Holse⁵, Søren Rasmussen⁵, Darren K McGuire^{1

2}

Affiliations

¹ Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
² Parkland Health and Hospital System, Dallas, Texas, USA.
³ Division of Endocrinology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
⁴ Department of Cardiology, Bnai Zion Medical Center, Haifa, Israel.
⁵ Novo Nordisk A/S, Søborg, Denmark.

No abstract available

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Cardiovascular Diseases* / chemically induced
Coronary Artery Disease*
Diabetes Mellitus, Type 2* / chemically induced
Glucagon-Like Peptides / adverse effects
Humans
Hypoglycemic Agents / adverse effects

Substances

semaglutide
Glucagon-Like Peptides
Hypoglycemic Agents

Grants and funding

T32 HL125247/HL/NHLBI NIH HHS/United States